Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Aug 07, 2024 9:56pm
139 Views
Post# 36168777

RE:Warma should resign

RE:Warma should resignGoldtech this bod is not driving the bus. Jeremy Sclar and Michael Gordon of the Boston group are the drivers. That's the risk Goldstein and Williams took when they brought these billionaires into the picture giving them now pocket change penny warrants. They own how much 30% of the stock throw in a few other Boston owners conbined with a low number of shareholders and low institutional ownership this is the result. Why do you think the price last year was quickly driven to $2 for their benefit. This Public company on the Nasdaq controlled by a few private people. Three years ago when the Canadian auditors brought ongoing concerns with the way the company was handling the preferred shares with the Boston group they were quickly ousted the next year. Not on the Nasdaq radar but likely the reason for getting rid of the tsx. Like i said 400 trading days in the last 1.5 years, 70% of shares traded in 3 trading days. Sums it up the Boston fix!

Was looking for the Alzheimers poster what a waste time these have been over the years. Did stumble onto a Manuscript posted July 29th. The same paper as posted April 30th. Have to download the pdf noticed 27 pages versus 19.  The difference a lot of emphasis on LMW and HMW.


<< Previous
Bullboard Posts
Next >>